The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Corticosteroids in brain cancer patients: benefits and pitfalls
Open accessAbstract
Glucocorticoids have been used for decades in the treatment of brain tumor patients and belong to the most powerful class of agents in reducing tumor-associated edema and minimizing side effects and the risk of encephalopathy in patients undergoing radiation therapy. Unfortunately, corticosteroids are associated with numerous and well-characterized adverse effects, constituting a major challenge in patients requiring long-term application of corticosteroids. Novel antiangiogenic agents, such as bevacizumab (Avastin®), which have been increasingly used in cancer patients, are associated with significant steroid-sparing effects, allowing neuro-oncologists to reduce the overall use of corticosteroids in patients with progressive malignant brain tumors. Recent experimental studies have revealed novel insights into the mechanisms and effects of corticosteroids in cancer patients, including modulation of tumor biology, angiogenesis and steroid-associated neurotoxicity. This article summarizes current concepts of using corticosteroids in brain cancer patients and highlights potential pitfalls in their effects on both tumor and neural progenitor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions
Persidsky, Y., Ramirez, S. H., Haorah, J., & Kanmogne, G. D. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9025-3 · Cited by 922
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848
Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi
Edman, J. C., Kovacs, J. A., Masur, H., Santi, D. V., Elwood, H. J., & Sogin, M. L. (1988) · Nature · doi:10.1038/334519a0 · Cited by 789
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
The human glucocorticoid receptor: molecular basis of biologic function
Nicolaides, N. C., Galata, Z., Kino, T., Chrousos, G. P., & Charmandari, E. (2010) · Steroids · doi:10.1016/j.steroids.2009.09.002 · Cited by 436
Molecular mechanisms of glucocorticoid action and resistance
Schaaf, M. J. M., & Cidlowski, J. A. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00263-7 · Cited by 416
Glucocorticoids in T cell apoptosis and function
Herold, M. J., McPherson, K. G., & Reichardt, H. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5390-y · Cited by 397
Glucocorticoid use in acute lymphoblastic leukaemia
Inaba, H., & Pui, C.-H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70114-5 · Cited by 367
Cited by
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Edlmann, E., Giorgi-Coll, S., Whitfield, P. C., Carpenter, K. L. H., & Hutchinson, P. J. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0881-y · Cited by 729
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 299
NLRC5/MHC class I transactivator is a target for immune evasion in cancer
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276
Siderophores: More than Stealing Iron
Behnsen, J., & Raffatellu, M. (2016) · mBio · doi:10.1128/mbio.01906-16 · Cited by 79
Metadata
- Authors
- Dietrich, J., Rao, K., Pastorino, S., & Kesari, S.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2011-03
- Volume
- 4
- Issue
- 2
- Pages
- 233-242
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2141713308
- Cited by
- 361
- References
- 60
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.